RedHill Biopharma has acquired exclusive commercialization rights to two FDA-approved gastrointestinal drugs, Rebyota and Clenpiq, from Ferring Pharmaceuticals, funded by the sale of its Talicia franchise. These drugs generated $37.5 million in net sales in 2025 and strengthen RedHill's commercial infrastructure and revenue potential. The company also highlighted ongoing R&D progress in oncology and Crohn's disease, aiming for portfolio expansion and operational growth. Financially, RedHill reported a net loss of $6.1 million for the first half of 2026 but improved liquidity and strategic positioning for future growth.
RedHill Biopharma's recent financial update includes a net loss of $6.1 million for the first half of 2026 and $37.5 million in net sales from newly acquired gastrointestinal drugs in 2025. For readers following the health sector, here is Pluang's market snapshot as of Oct 01, 2026 03:02 WIB: out of 100 priced US health stocks, 30 rose and 69 fell. Notable movers include HIMS at USD 29.90 with 99% buy order activity, TWST at USD 193.50 with 98% buy order activity, and SMMT at USD 16.96 with 100% sell order activity.
Loans backed by Bitcoin and stablecoins have become eligible within Fannie Mae's mortgage framework through administrative decisions rather than market-driven validation. This development is significant as it represents a major step for crypto credit...
Rosen Law Firm has filed a class action lawsuit against Better Home & Finance Holding Company for allegedly making false and misleading statements about its $1 billion monthly funded volume target during March to May 2026. The lawsuit claims the comp...
HireQuest Inc. is rated Buy due to its asset-light staffing model that cuts costs and boosts profitability. The stock has surged over 80% year-to-date, driven by strong manufacturing hiring and a solid pipeline of national accounts with visibility in...
Royce Global Trust, a closed-end fund focusing on global small- and mid-cap equities using a value approach, reported a one-year total return of 21.7% as of August 31, 2026. The fund invests at least 80% of its assets in equity securities, with a sig...
Advanced Micro Devices (AMD) has been upgraded to a Buy rating following its $8.2 billion acquisition of World Labs, which enhances its capabilities in frontier and physical AI. The deal strengthens AMD's AI ecosystem, brings in top talent, and posit...
